New Polymeric Material can Replace Antibodies for Disease Diagnostics

New Polymeric Material can Replace Antibodies for Disease Diagnostics

immune-system-1359197_960_720

Biotechnology experts at the University of Leicester have revealed that their team have developed polymeric materials that exhibit the capability to recognize molecules much more efficiently than natural antibodies, which may prove to be a boon for the disease diagnostic applications going forward.

Working in association with an independent company called MIP Diagnostics Ltd., scientists at the U.K. University announced that their team have successfully managed to demonstrate that molecular imprinting technique can produce polymer nanoparticles with an ability to attach to targeted molecules in a much stronger way than currently commercially used antibodies. Currently available antibodies frequently fail against challenging targets but this new polymeric material can overcome the limitations.

In addition to that, the manufacturing of these polymeric materials is easy, less time consuming, and can attain high affinity besides doing without the requirements of a cold chain logistics. These particular features makes them a strongly attractive over common antibodies used for immunoassays.

The results of the research assured that MIP nanoparticles can be utilized as logical alternates to antibody in ELISA format, performing much better than natural receptors that antibodies are. These assays are much more stable, which will lead to its quicker adoption for various industrial applications as far as diagnostic procedures are concerned.

According to Sergey Piletsky, the lead researcher of this study, it has been more than two decades since the inaugural demonstration of polymers that were molecularly imprinted and can be used in clinically significant drugs. The latest advancements in the synthesis of MIP nanoparticles can vanquish the drawbacks of MIPs in terms of leading for the problems pertaining to binding kinetics, lack of ideal industrial manufacturing protocol, and binding side heterogeneity.